Cullinan Therapeutics Inc News - CGEM

FeaturedSouthern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023

CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a...

Additional Proxy Soliciting Materials (definitive) (defa14a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Cullinan Oncology to Participate in Stifel’s 2023 Targeted Oncology Days

CAMBRIDGE, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Statement of Changes in Beneficial Ownership (4)

FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines

CAMBRIDGE, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a...

Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting

CLN-619 is a MICA/B directed humanized IgG1 antibody being studied in a global Phase 1 clinical trial in...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Cullinan Therapeutics Inc (CGEM)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

CGEM News

FeaturedSouthern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project

Statement of Changes in Beneficial Ownership (4)

Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023

Additional Proxy Soliciting Materials (definitive) (defa14a)

Statement of Changes in Beneficial Ownership (4)

Cullinan Oncology to Participate in Stifel’s 2023 Targeted Oncology Days

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines

Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting

Securities Registration: Employee Benefit Plan (s-8)

Securities Registration Statement (simplified Form) (s-3)

Annual Report (10-k)

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Cullinan Oncology to Participate in Cowen’s 43rd Annual Health Care Conference

CGEM Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Cullinan Therapeutics Inc (CGEM) News

Cullinan Therapeutics Inc (CGEM)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

CGEM News

FeaturedSouthern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project

Statement of Changes in Beneficial Ownership (4)

Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023

Additional Proxy Soliciting Materials (definitive) (defa14a)

Statement of Changes in Beneficial Ownership (4)

Cullinan Oncology to Participate in Stifel’s 2023 Targeted Oncology Days

Statement of Changes in Beneficial Ownership (4)

Statement of Changes in Beneficial Ownership (4)

Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines

Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting

Securities Registration: Employee Benefit Plan (s-8)

Securities Registration Statement (simplified Form) (s-3)

Annual Report (10-k)

Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results

Cullinan Oncology to Participate in Cowen’s 43rd Annual Health Care Conference

CGEM Discussion

Your Recent History